Virginia
Bill would regulate GLP-1 compounding.
November 17, 2026
Virginia Bill Would Regulate GLP-1 Compounding Read more

Our Perspective
AmSpa's Take
There has been a growing national trend to more tightly regulate compounding of medication. Please note this is a carryover bill from 2026, and similar legislation was introduced last year in Indiana and Colorado.
Detailed Analysis
Analysis
Bill Name: House Bill 917 (HB 917)
Primary Sponsor: Del. Rodney Willett and Del. Elizabeth Guzman
Status: 11/17/2026 Left in Committee Health and Human Services
AmSpa’s Take: There has been a growing national trend to more tightly regulate compounding of medication. Please note this is a carryover bill from 2026, and similar legislation was introduced last year in Indiana and Colorado.
Analysis: Currently in Virginia, as in most states, compounding rules are primarily directed at regulating the practice of pharmacies and cover the practice broadly. If passed, HB 917 would create additional requirements for compounding pharmacies regarding the sourcing of the underlying bulk drug substances used to produce the medication.
HB 917 would require that the compounding pharmacy use bulk drug substance that appears on a list developed by the FDA:
- The bulk drug substance is pharmaceutical grade, as shown by the certificate of analysis or other documentation;
- The bulk drug substance has a valid certificate of analysis that includes all material safety and effectiveness information, including its identity and content, country of original manufacture, identity and amount of impurities, and any additional information required by the Board;
- The pharmacist obtains proof that the bulk drug substance was manufactured at a facility that is registered with the FDA and inspected by the FDA within the past two years as a human drug establishment, including for current good manufacturing practices and the relevant bulk drug substance, with an inspection classification of “voluntary action indicated” or “no action indicated”;
- Before using the bulk drug substance, the pharmacist conducts and documents, or obtains documentation of, quality control testing confirming the substance’s identity and content; and that any impurities have been identified, characterized, quantified, and justified for the product and its intended use; and
- The bulk drug substance otherwise complies with the Federal Food, Drug, and Cosmetic Act.
Pharmacists are also prohibited from compounding drugs that use a bulk drug substance that appears on an FDA list of drugs that have been withdrawn or removed from the market for reasons of safety. Additionally, pharmacists may not compound inordinate amounts of drugs that are essentially copies of commercially available drug products. Under HB 917, “essentially a copy” means a drug that includes the same bulk drug substances as a commercially available drug unless there is a clinically significant difference or change as determined by the prescribing practitioner or the drug is needed to meet an emergency life threatening situation and the commercial product is unavailable. The reasons for the need for the clinically significant difference must be documented by the prescriber.
With the popularity of GLP-1 based medication and the increasing popularity if peptides, multiple states have introduced bills aimed at more closely regulating compounding of medications. If you would like additional information, to read the language of this bill or to contact the sponsors or committee, you can find the information you need through here: HB 917.